A personalized prediction scheme for certain chronic blood cancers has been developed, based on new disease classifications.
Browsing: Disease Area > Hematologic
Adult cancer patients in England will receive the new game-changing CAR-T therapy Yescarta® under the first negotiated deal of its kind struck in Europe.
The ground breaking CAR-T therapy – Kymriah® – is set to become the first personalized cancer therapy available on the NHS.
Yescarta®, a novel personalized CAR T cell therapy has been approved for use in Europe by the EMA but has received a draft negative guidance from NICE.
The largest ever study of its kind has become the first to definitively show an increased risk of blood cancers in relatives of patients.
A multi-disciplinary team of researchers have developed comprehensive CAR T-cell therapy pediatric guidelines.
The FDA has approved TIBSOVO – the first oral, targeted therapy for relapsed/ refractory acute myeloid leukemia (R/R AML) adults patients and an IDH1 mutation.
This database study demonstrates variations in the utilization of hematopoietic cell transplantation in adult patients with acute lymphoblastic leukemia based on several biological and non-biological factors.